Literature DB >> 1341991

Management of psychotropic-induced hyperprolactinemia.

P A Marken1, R F Haykal, J N Fisher.   

Abstract

The effects of individual psychotropic medications on serum prolactin concentrations are described, and recommendations for dealing with adverse effects are provided. Hyperprolactinemia can result in galactorrhea, amenorrhea, irregular menses, and anovulation; in men, impotence and azoospermia, with or without lactation and gynecomastia, can occur. Antipsychotics may block dopamine receptors in the pituitary prolactin-secreting cells and prevent dopamine-induced reduction of prolactin release. The magnitude of the increase in prolactin concentration correlates with the amount of antipsychotic drug given. The treatment of choice is reduction of the antipsychotic dosage or discontinuation of therapy. If adjustments to the antipsychotic dosage fail to resolve symptoms, the dopamine agonists bromocriptine and amantadine may be tried. Antidepressants may produce elevated serum prolactin concentrations, especially with long-term administration. However, the frequency of antidepressant-induced hyperprolactinemia is much lower than that seen with antipsychotics, and serious adverse clinical effects are uncommon. Other psychotropic drugs such as lithium, valproic acid, buspirone, carbamazepine, and benzodiazepines either are only rarely associated with symptomatic hyperprolactinemia or do not produce clinically important changes in prolactin concentrations. Antipsychotic drugs are the psychotropic agents most likely to cause symptomatic hyperprolactinemia. Bromocriptine or amantadine may provide symptomatic relief if withdrawal or adjustment of the antipsychotic dosage does not eliminate the symptoms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341991

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  16 in total

1.  Olanzapine-induced galactorrhea.

Authors:  Rasmus W Licht; Torben Arngrim; Hilmar Cristensen
Journal:  Psychopharmacology (Berl)       Date:  2002-06       Impact factor: 4.530

2.  Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.

Authors:  S R Tollin
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

3.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 4.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 5.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.

Authors:  J A Den Boer; H J van Megen; W W Fleischhacker; J W Louwerens; B R Slaap; H G Westenberg; G D Burrows; O N Srivastava
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 7.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS.

Authors:  V P Matei; T Purnichi; A Mihailescu; R Grigoras
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

9.  Osteoporosis associated with antipsychotic treatment in schizophrenia.

Authors:  Haishan Wu; Lu Deng; Lipin Zhao; Jingping Zhao; Lehua Li; Jindong Chen
Journal:  Int J Endocrinol       Date:  2013-04-17       Impact factor: 3.257

10.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.